- RecruitingPHASE1
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
This study is testing a new combination of treatments for advanced pancreatic neuroendocrine tumours. We want to see if adding sunitinib malate to lutetium Lu 177 dotatate is safe and effective. This research aims to find better ways to fight these specific cancers.
For: Metastatic Pancreatic Neuroendocrine Tumor · Pancreatic Neoplasm · Stage III Pancreatic Neuroendocrine Tumor AJCC v8United States · Canada - Active not recruitingPHASE3
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
This study is for people with advanced kidney cancer (non-clear cell type) that hasn't spread too widely. It compares a new combination of drugs (XL092 + nivolumab) with a standard treatment (sunitinib) to see which works better. Participants haven't had prior cancer medicine for their advanced kidney cancer.
For: Non-Clear Cell Renal Cell CarcinomaUnited States · Argentina · Australia